Orexo licenses respiratory program to AstraZeneca

01/29/2013 | PharmaTimes (U.K.)

Sweden's Orexo granted AstraZeneca the right to carry out further preclinical work and evaluation of compounds in its OX-CLI program targeted for respiratory diseases. AstraZeneca was also given the option to purchase the compounds in the program. The deal entitles Orexo to possible milestone fees and royalties.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX